



CD44v8-10 and CD44s Are Age-dependently Expressed in Primary Cultured Papillary Thyroid Carcinoma Cells and Are Associated with Cell Proliferation

Kawai, Takeo ; Iwata, Keisuke ; Shinotsuka, Yuna ; Kubo, Sayaka ; Masuoka, Hiroo ; Yabuta, Tomonori ; Hirokawa, Mitsuyoshi ; Nakamura,...

(Citation)

The Kobe journal of the medical sciences, 65(1):1-9

(Issue Date)

2019

(Resource Type)

departmental bulletin paper

(Version)

Version of Record

(JaLCD0I)

<https://doi.org/10.24546/81011263>

(URL)

<https://hdl.handle.net/20.500.14094/81011263>



CD44v8-10 and CD44s Are Age-dependently Expressed in Primary Cultured Papillary Thyroid Carcinoma Cells and Are Associated with Cell Proliferation

TAKEO KAWAI^{1,2}, KEISUKE IWATA¹, YUNA SHINOTSUKA¹, SAYAKA KUBO¹, HIROO MASUOKA³, TOMONORI YABUTA³, MITSUYOSHI HIROKAWA⁴, HIROTOSHI NAKAMURA⁵, AKIRA MIYAUCHI³ and KOICHIRO KOMAI^{1,*}

¹*Division of Medical Biophysics, Department of Biophysics, Graduate School of Health Sciences, Kobe University, Kobe, Japan*

²*Department of Clinical Laboratory, Kuma Hospital, Kobe, Japan*

³*Department of Surgery, Kuma Hospital, Kobe, Japan*

⁴*Department of Diagnostic Pathology, Kuma Hospital, Kobe, Japan*

⁵*Department of Internal Medicine, Kuma Hospital, Kobe, Japan*

Received 12 November 2018/ Accepted 7 January 2019

Keywords: Papillary thyroid carcinoma, Aging, CD44, Splice variant

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, arising from follicular cells, and accounts for more than 80% of all thyroid malignant tumors. Although age is the strongest prognostic factor of PTC, and various cut-off ages (40-55 years) were suggested in previous studies, the molecular mechanisms causing age-related changes of PTC cell proliferation remain unclear. CD44 is a major cell surface receptor for hyaluronate and is known as a cancer stem cell marker. However, the association between CD44 and PTC is still unknown. Therefore, we determined the proliferation of primary cultured cells obtained from patients with PTC, and the CD44 mRNA expression profile to elucidate age-related association of CD44 with PTC. The results showed that cell proliferation was significantly decreased according to age. We also found that CD44v8-10 and CD44 splice variants were expressed dominantly in patients with PTC. Moreover, the CD44v8-10/CD44s mRNA expression ratio was significantly increased according to age, and there was a significant negative correlation between this expression ratio and cell proliferation. Our findings suggest that the CD44v8-10/CD44s expression ratio in PTC cells is useful for screening for aggressive PTC and may provide clinically valuable information.

INTRODUCTION

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy arising from follicular cells and accounts for more than 80% of all thyroid malignant tumors. PTC generally has indolent characteristics and grows very slowly. However, PTC often spreads to cervical lymph nodes and distant organs such as the lung, bone, and brain (16,19,24,44).

Previous studies identified several prognostic factors of PTC such as age, sex, tumor size, extra-thyroidal extension, node metastasis, and distant metastasis (6,13,17). Especially, age was the strongest prognostic factor and various classifications of cut-off ages (40-55 years) were suggested (3,12,15,38,41). Miyauchi *et al.* reported that thyroglobulin-doubling time was a very strong prognostic predictor and had a strong correlation with patients' age (28,29). On the other hand, Mazzaferri *et al.* reported that lymph node recurrences were most frequent at the extremes of age (< 20 and > 59 years) (23), and the same trend was reported by Ito *et al.* (18). Nevertheless, the exact reason for this trend is still unclear.

Recent studies suggest that CD44, one of the most common cancer stem cell (CSC) markers, and its variants (CD44v) by alternative splicing, are related to the progression of several cancers (9,20). CD44 has been implicated in various roles including leukocyte homing and activation, wound healing and cell migration, as well as tumor cell invasion and metastasis (11,31,34). On the other hand, CSCs have the ability to self-renew and to differentiate (14). These facts suggest that CD44 might have some cancer-specific role. Therefore, we determined the expression of CD44 mRNA and cell proliferation activity with primary cultured cells derived from PTC tumors, and analyzed the association with patients' age.

MATERIAL AND METHODS

Patients and tissue samples

The patient cohort consisted of 27 females and 13 males, aged from 16 to 79 years (44.2 ± 16.8 ; median = 43). Clinical data are shown in Table I. All PTC tissues were removed surgically and provided by Kuma Hospital (Kobe, Japan) from April 2014 to July 2017. The study was approved by the institutional ethical committee of the Graduate School of Health Sciences, Kobe University, and was carried out according to the Declaration of Helsinki principles (Permission Number: 275-1).

Table I. Clinical data of recruited patients with PTC

No.	Sex	Age	TNM	pT	pN	pEx	DM
1	F	79	2	3	1a	1	-
2	M	55	4	3	1b	1	Lung
3	F	54	1	2	1b	0	-
4	F	44	1	3	1b	1	-
5	M	26	2	3	1b	1	Lung
6	F	72	2	*	1b	0	-
7	M	34	1	3	1b	0	-
8	M	65	2	3	1b	1	-
9	F	16	1	3	1b	1	-
10	M	72	2	3	1b	0	-
11	M	56	1	3	1b	1	-
12	F	43	1	3	1a	1	-
13	F	21	1	2	1a	0	-
14	F	22	1	2	1a	0	-
15	F	28	1	2	1b	0	-
16	F	70	2	3	1b	1	-
17	F	54	1	3	1b	1	-
18	F	52	1	3	1b	0	-
19	F	27	1	3	1b	1	-
20	F	23	1	3	1b	1	-
21	F	58	1	3	1b	1	-
22	M	33	1	3	1b	0	-
23	F	47	2	2	1b	0	Lung
24	M	43	1	3	1a	1	-
25	F	62	2	3	1b	1	-
26	M	35	1	3	1b	1	-
27	F	46	1	3	1b	0	-
28	F	33	1	3	1b	1	-
29	M	31	1	3	1b	1	-
30	M	31	2	3	1b	1	Lung
31	M	62	2	3	1b	1	-
32	M	21	1	3	1b	1	-
33	F	66	2	3	1b	1	-
34	F	60	2	3	1a	1	-
35	F	23	1	2	1a	0	-
36	F	45	1	2	1a	0	-
37	F	41	1	3	1a	1	-
38	F	36	1	2	1a	0	-
39	F	39	1	3	1b	1	-
40	F	43	1	3	1a	1	-

F, Female; M, Male; TNM, AJCC TNM staging; pT, pathological tumor status; pN, pathological nodal status; pEx, pathological extrathyroidal extension; DM, distant metastasis; *, Meta LN recurrence

Cell culturing

The basic culture medium was Dulbecco's modified Eagle's medium (DMEM; Nissui Pharmaceutical Company, Tokyo, Japan) supplemented with penicillin (100 IU/mL), streptomycin (100 µg/mL), L-glutamine (2 mM), sodium bicarbonate (0.195%) (all from Thermo Fisher Scientific, Waltham, MA, USA), and 10% fetal bovine serum (Biowest, Miami, FL, USA).

The primary culture method was based on the procedure described by Miller *et al.* (25). PTC tissues (0.6 g wet weight) were placed immediately in DMEM at 4°C. Within 24 h, the tissues were minced into 1 mm³ pieces in DMEM, followed by incubation at 37°C with shaking for 2 h in phosphate-buffered saline containing 0.3 U/mL type II collagenase (Worthington Diagnostic Systems, Freehold, NJ, USA). To remove cell aggregates, the resulting suspensions were filtered through a 100 µm cell strainer (Greiner Bio-One, Monroe, NC, USA) and the cells were washed two times with DMEM. The cell suspensions were put into 75 cm² culture flasks with vented caps (Iwaki Glass, Tokyo, Japan) and placed in an incubator at 37°C with 5% CO₂.

RNA extraction and the real-time polymerase chain reaction (RT-PCR) for CD44

Total RNA was extracted from primary cultured PTC cells using TRIzol reagent (Life Technologies, Carlsbad, CA, USA). cDNAs were reverse-transcribed using the PrimeScript II First Strand cDNA Synthesis Kit (Takara Bio, Kusatsu, Japan) following the manufacturer's protocol. The 35 cycles of PCR amplification were performed at 94°C for 30 sec, 60°C for 30 sec, and 72°C for 1 min by using TaKaRa Ex Taq Polymerase (Takara Bio). Primer pairs were purchased from Sigma-Aldrich (St. Louis, MO, USA) and sequences were as follows: forward, 5' - GAGCAGCACTTCAGGAGGTT-3' (hCD44-992F); reverse, 5' -GGGTGGAATGTGTCTTGCTC-3' (hCD44-2247R). The PCR products were electrophoresed on 1.0% agarose gels and sequenced by Eurofins Genomics (Tokyo, Japan).

Quantitative (q)RT-PCR of CD44

CD44v8-10 and CD44s mRNA expression levels were measured quantitatively by the qRT-PCR using Taqman® Gene Expression Assays (IDs: Hs01081475_m1, Hs01081473_m1) and Taqman® Universal PCR Master Mix (Thermo Fischer) following the manufacturer's protocols (Patient ID: 10, 11, 13, 14, 15, 17, 19, 20, 21, 23, 24, 26, 27, 28, 29, 31, 32 and 33 as shown in Table I.). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Hs02758991_g1) was used as the reference gene. The relative expression ratio of CD44/GAPDH mRNAs was determined.

Cell proliferation assay

Cell proliferation was measured using the Premix WST-1 Cell Proliferation Assay System (Takara Bio). After 7–10 days of incubation, the culture medium was removed, and PTC cells (Patient ID: 1-40 as shown in Table I.) were harvested using a trypsin/EDTA solution (Clonetics Lonza, Walkersville, MD, USA). The cells were then plated in triplicate in 96-well plates at a density of 1×10^4 cells/well, followed by incubation for another 48 h after which 10 µL of WST-1 (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) reagent were added to each well. After 2 h at 37°C, the absorbance of each well was measured at 450 nm (reference: 655 nm).

Statistical analyses

Age-related differences in PTC cell proliferation were determined by a one-way analysis of variance, Welch's t-test, and Pearson's correlation analysis. Correlations between CD44v8-10 or CD44s mRNA expression levels and patient's age or cell proliferation activity were determined by Pearson's correlation analysis using 'EZR' (Easy R) statistical software. Data are expressed as means ± standard deviation. A *P*-value less than 0.05 was considered statistically significant.

RESULTS

Cell proliferation was significantly decreased with age

To elucidate the correlation between PTC cell proliferation and age, the proliferation of primary cultured PTC cells was measured using the WST-1 assay. The proliferation of PTC cells after 48 h of culturing from the young (under 40 years of age), middle-aged (40-59 years of age), and elderly (over 60 years of age) groups were 1.12 ± 0.52 , 0.859 ± 0.463 , and 0.631 ± 0.269 (absorbance at 450 nm), respectively. Significant differences were observed in cell proliferation among the three age groups; cell proliferation of the young group was significantly higher than that of the elderly group (*P* < 0.05) (Fig. 1A). Additionally, cell proliferation activity was significantly decreased according to age (*P* < 0.05) (Fig. 1B).




Figure 1. Proliferation of papillary thyroid carcinoma cells.

(A) Cell proliferation according to age groups, analyzed by using a one-way analysis of variance and Welch's t-test. N= 17 (<40), 14 (40-59), 9 (60≤)

(B) Correlation between age and cell proliferation analyzed using Pearson's correlation analysis. N=40 *P < 0.05

CD44v8-10 and CD44s mRNAs were expressed dominantly in PTC cells and the expression levels varied significantly among age groups

CD44 is the most common CSC marker and is widely expressed on the cell surface. Various isoforms of CD44 formed by alternative splicing are associated with the progression of many cancers (32,33,45). Therefore, we investigated mRNA levels of the CD44 variant isoforms using the qRT-PCR. The results showed that the CD44v8-10 and CD44s variants were expressed dominantly in patients with PTC (Fig. 2A).

We next investigated the correlation between CD44v8-10 mRNA expression and patient's age. Relative to GAPDH, significantly different expression levels of CD44v8-10 were found between the young (36.6 ± 13.5), middle-aged (57.4 ± 23.4), and elderly (27.3 ± 17.3) groups. The expression level of CD44v8-10 mRNA in the middle-aged group was significantly higher than that of the elderly group (Fig. 2B). There was no correlation between the CD44v8-10 mRNA expression level and patient's age (Fig. 2C).

We also examined the expression level of CD44s mRNA. Unlike the tendency with CD44v8-10, no significant changes of CD44s mRNA were found between age groups (young: 11.3 ± 8.62 , middle-aged: 5.38 ± 3.28 , elderly: 4.39 ± 4.87) (Fig. 2D). However, the CD44s mRNA expression level was significantly decreased according to age (Fig. 2E).

CD44 VARIANTS ARE AGE-DEPENDENTLY EXPRESSED IN PTC CELLS




Figure 2. Identification and quantification of CD44s and CD44v8-10 mRNAs in papillary thyroid carcinoma cells.

Expression levels were calculated as the relative expression ratio of CD44/GAPDH.

(A) Typical results of the RT-PCR for CD44 mRNA

(B) CD44v8-10 mRNA expression levels according to age groups analyzed by a one-way analysis of variance and Welch's t-test. Patient ID: 10, 11, 13, 15, 18, 19, 20, 23, 24, 25, 26, 27, 28, 29, 30, 32 and 33, as shown in Table I. N= 6 (<40), 6 (40-59), 5 (60≤)

(C) CD44v8-10 mRNA expression levels according to age analyzed by Pearson's correlation analysis.

(D) CD44s mRNA expression levels according to age groups analyzed by a one-way analysis of variance and Welch's t-test. Patient ID: 10, 11, 13, 14, 15, 17, 19, 20, 21, 23, 24, 26, 27, 28, 29, 31, 32 and 33, as shown in Table I. N= 9 (<40), 6 (40-59), 3 (60≤)

(E) CD44s mRNA expression levels according to age analyzed by Pearson's correlation analysis. * $P < 0.05$

The CD44v8-10/CD44s expression ratio was significantly increased according to age, and there was a significant correlation between this ratio and cell proliferation

The CD44v8-10/CD44s mRNA expression ratio has been suggested as a novel prognostic predictor in patients with urothelial cancer (26). Therefore, we compared this ratio in PTC cells between age groups. The results showed significant differences among the three age groups (young: 3.04 ± 2.44 , middle-aged: 13.20 ± 4.72 , elderly: 26.9 ± 15.4). The CD44v8-10/CD44s expression ratio of the young group was significantly lower than that of the middle-aged group (Fig. 3A). Additionally, the CD44v8-10/CD44s expression ratio was significantly increased according to age (Fig. 3B). We also observed a correlation between the CD44v8-10/CD44s expression ratio and cell proliferation; the ratio was significantly decreased according to cell proliferation activity (Fig. 3C).




Figure 3. Correlations between the CD44v8-10/CD44s mRNA expression ratio and age, and papillary thyroid carcinoma cell proliferation.

(A) CD44v8-10/CD44s expression ratios according to age groups analyzed by a one-way analysis of variance and Welch's t-test. Patient ID: 10, 11, 13, 15, 19, 20, 23, 24, 26, 27, 29 and 32, as shown in Table I. N= 5 (<40), 5 (40-59), 2 (60+)

(B) CD44v8-10/CD44s expression ratios according to age analyzed by Pearson's correlation analysis.

(C) CD44v8-10/CD44s expression ratios according to cell proliferation analyzed by Pearson's correlation analysis. Patient ID: 10, 11, 13, 15, 19, 20, 23, 24, 27 and 32, as shown in Table I.

* $P < 0.05$

DISCUSSION

In this study, we used the WST-1 assay with primary cultured PTC cells and found significantly higher proliferation in cells from young patients as compared with other age groups. We also found a significant correlation between cell proliferation and age. These results are clinically plausible because young patients usually present with more aggressive disease characteristics than older patients (8,18). Ito *et al.* reported that the lymph node recurrence rate was high in young and elderly patients, although the carcinoma death rate was elevated only in elderly patients (18). Another study with patients younger than age 45 years reported that cervical lymph node metastasis should be recognized as a prognostic indicator (1). Our findings suggest that not only metastasis but also increased proliferation activity cause the unfavorable pathological condition of young patients as compared with other age groups. Further investigations are needed to determine the proliferation activity of cells from other major histological types of thyroid cancer and normal thyroid tissue according to age.

CD44 has a wide variety of splice variants. We found that the CD44v8-10 and CD44s variants were expressed dominantly in patients with PTC. Exons 1-5 and 16-20 are constitutive exons, and the standard isoform (known as CD44s or CD44E), without exon 6-15 (variant exon 1-10), is the most dominant isoform (34,35). CD44v have lower affinity for hyaluronate than that of CD44s (27,37). Furthermore, the ligand-binding specificity of CD44v can be changed, and cell migration and growth are also affected by the extracellular domain of CD44, including

variant exons (39,42). It has been reported that dysregulation of mRNA alternative splicing can lead to aging or age-related diseases. Alternative splicing changes during physiological aging were recognized in multiple human tissues (22). How CD44 and its variant expression levels are changing with aging is not still elucidated. However, it has been reported that the MAPK-ERK pathway regulates alternative splicing of CD44 (43). As we found the age-related differences of the proliferation of PTC cells, it is suggested that cell proliferation change *via* the MAPK-ERK pathway could affect the splicing of CD44.

Previous studies reported that CD44 and its variants were found in several human malignancies and exhibited relationships with cancer progression and metastasis (20,31). It has been demonstrated that CD44v8-10 is expressed in patients with different human epithelial cancers, including breast, colorectal, urothelial, and gastric cancer, and its expression correlates with metastasis (26,45). A previous study also reported that overexpression of CD44v8-10 decreased its interaction with hyaluronate in bladder cancer cells, and it was suspected that these processes resulted in abnormal signal transduction from the extracellular domain and enhanced malignant potential (30). These findings suggest that an increased expression ratio of CD44v8-10/CD44s enhances malignant potential and is associated with tumorigenicity of cancer.

Previous studies using immunohistochemistry also showed that CD44 isoforms were found in patients with PTC (4,7,10,21). Furthermore, the expression ratio of CD44v/CD44s was significantly higher in PTC than normal thyroid cells (40). In this study, we found that CD44v8-10 was the dominant form of CD44v in PTC cells and the expression ratio of CD44v8-10/CD44s mRNA was significantly increased according to age. We also found that there was a negative correlation between the CD44v8-10/CD44s expression ratio and proliferation activity. We examined the associations of CD44v8-10/CD44s expression ratio and TNM classification, lymph node metastasis, and tumor invasion. As the result, while no associations were found between CD44v8-10/CD44s expression ratio and AJCC TNM staging or tumor invasion, CD44v8-10/CD44s expression ratio were 5.96 and 12.32, in cases with lymph node metastasis pN1a (n=2) and pN1b (n=10), respectively. However, there was no significant difference. Meanwhile, because it has been reported that CD44 variants are associated with EMT (epithelial-mesenchymal transition), we think further investigation of those association study is needed (5).

Böhm *et al.* also reported that low CD44s expression was an independent prognostic factor for the recurrence of differentiated thyroid carcinoma (2). Based on this report, our results suggest that, while the prognosis of young patients is mainly associated with increased cell proliferation rather than the decreased expression ratio of CD44v8-10/CD44s, the prognosis of elderly patients is mainly associated with the tumorigenicity according to the increased expression ratio of CD44v8-10/CD44s. Previous studies have used the TNM classification of the Union for International Cancer Control to propose cut-off ages as a risk factor based on the clinical characteristics of PTC (36). Although it is unknown the duration of morbidity in the recruited patients in this study, our results may provide evidence to set the clinical cut-off age of patients with PTC.

Overall, our findings suggest that the aggressive behavior of PTC cells and mortality have different mechanisms according to age. Our results also suggest that quantitative determination of the CD44v8-10/CD44s mRNA expression ratio of PTC cells could provide clinically valuable information, such as screening for aggressive PTC for pre-and post-operative follow up.

ACKNOWLEDGEMENTS

The authors would like to thank Professor Shingo Kamoshida for valuable opinions and warm encouragements. The authors would also like to express their gratitude to the members of the diagnostic pathology department. The authors also appreciate all members in their laboratory for their support. The authors also would like to thank Editage (www.editage.jp) for English language editing.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES

1. Adam, M.A., Pura, J., Goffredo, P., Dinan, M.A., Reed, S.D., Scheri, R.P., Hyslop, T., Roman, S.A., and Sosa, J.A. 2015. Presence and Number of Lymph Node Metastases Are Associated with Compromised Survival for Patients Younger Than Age 45 Years with Papillary Thyroid Cancer. *J Clin Oncol* **33**: 2370–2375.
2. Böhm, J.P., Niskanen, L.K., Pirinen, R.T., Kiraly, K., Kellokoski, J.K., Moisio, K.I., Eskelinen, M.J., Tulla, H.E., Hollmen, S., Alhava, E.M., and Kosma, V.M. 2000. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma. *J Pathol* **192**: 321–327.
3. Cady, B., and Rossi, R. 1988. An expanded view of risk-group definition in differentiated thyroid carcinoma. *Surgery* **104**: 947–953.

4. **Chhieng, D.C., Ross, J.S., and Mckenna, B.J.** 1997. CD44 Immunostaining of Thyroid Fine-Needle Aspirates Differentiates Thyroid Papillary Carcinoma from Other Lesions with Nuclear Grooves and Inclusions. *Am Cancer Soc* **81**: 157–162.
5. **Cieply, B., Koontz, C., and Frisch, S.M.** 2015. CD44S-hyaluronan interactions protect cells resulting from EMT against anoikis. *Matrix Biol* **48**: 55–65.
6. **Eichhorn, W., Tabler, H., Lippold, R., Lochmann, M., Schreckenberger, M., and Bartenstein, P.** 2003. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. *Thyroid* **13**: 949–958.
7. **Figge, J., del Rosario, A.D., Gerasimov, G., Dedov, I., Bronstein, M., Troshina, K., Alexandrova, G., Kallakury, B.V., Bui, H.X., Bratslavsky, G., and Ross, J.S.** 1994. Preferential expression of the cell adhesion molecule CD44 in papillary thyroid. *Histopathology* **61**: 203–211.
8. **Girardi, F.M.** 2017. Thyroid Carcinoma Pattern Presentation According to Age. *Int Arch Otorhinolaryngol* **21**: 38–41.
9. **Go, S., Ko, G.H., Lee, W.S., Kim, R.B, Lee, J.H., Jeong, S.H., Lee, Y.J., Hong, S.C., and Ha, W.S.** 2016. CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer. *Cancer Res Treat* **48**: 142–152.
10. **Gu, J., Daa, T., Kashima, K., Yokoyama, S., Nakayama, I., and Noguchi, S.** 1998. Expression of splice variants of CD44 in thyroid neoplasms derived from follicular cells. *Pathol Int* **48**: 184–190.
11. **Günthert, U., Hofmann, M., Rudy, W., Reber, S., Zöller, M., Haussmann, I., Matzku, S., Wenzel, A., Ponta, H., and Herrlich, P.** 1991. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. *Cell* **65**:13–24.
12. **Hay, I.D., Bergstralh, E.J., Goellner, J.R., Ebersold, J.R., and Grant, C.S.** 1993. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. *Surgery* **114**: 1050-7; discussion 1057-1058.
13. **Hay, I.D., Grant, C.S., Taylor, W.F., and McConahey, W.M.** 1987. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. *Surgery* **102**: 1088–1095.
14. **Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., Masuko, T., Shimizu, T., Ishikawa, T., Kai, K., Takahashi, E., Imamura, Y., Baba, Y., Ohmura, M., Suematsu, M., Baba, H., and Saya, H.** 2011. CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc- and Thereby Promotes Tumor Growth. *Cancer Cell* **19**: 387–400.
15. **Ito, Y., Ichihara, K., Masuoka, H., Fukushima, M., Inoue, H., Kihara, M., Tomoda, C., Higashiyama, T., Takamura, Y., Kobayashi, K., Miya, A., and Miyauchi, A.** 2010. Establishment of an Intraoperative Staging System (iStage) by Improving UICC TNM Classification System for Papillary Thyroid Carcinoma. *World J Surg* **34**: 2570–2580.
16. **Ito, Y., Kudo, T., Kobayashi, K., Miya, A., Ichihara, K., and Miyauchi, A.** 2012. Prognostic Factors for Recurrence of Papillary Thyroid Carcinoma in the Lymph Nodes, Lung, and Bone: Analysis of 5768 Patients with Average 10-year Follow-up. *World J Surg* **36**: 1274–1278.
17. **Ito, Y., Miyauchi, A., Jikuzono, T., Higashiyama, T., Takamura, Y., Miya, A., Kobayashi, K., Matsuzuka, F., Ichihara, K., and Kuma, K.** 2007. Risk Factors Contributing to a Poor Prognosis of Papillary Thyroid Carcinoma: Validity of UICC/AJCC TNM Classification and Stage Grouping. *World J Surg* **31**: 838–848.
18. **Ito, Y., Miyauchi, A., Kihara, M., Higashiyama, T., Kobayashi, K., and Miya, A.** 2014. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. *Thyroid* **24**: 27–34.
19. **Ito, Y., Miyauchi, A., Kihara, M., Higashiyama, T., Kobayashi, K., and Miya, A.** 2014. Prognostic significance of young age in papillary thyroid carcinoma : Analysis of 5733 patients with 150 months' median follow-up. *Endocr J* **61**: 491-497.
20. **Jordan, A.R., Racine, R.R., Hennig, M.J.P., and Lokeshwar, V.B.** 2015. The role of CD44 in disease pathophysiology and targeted treatment. *Front Immunol* **6**: 182.
21. **Kurozumi, K., Nakao, K., Nishida, T., Nakahara, M., Ogino, N., and Tsujimoto, M.** 1998. Significance of biologic aggressiveness and proliferating activity in papillary thyroid carcinoma. *World J Surg* **22**: 1237–1242.
22. **Li, H., Wang, Z., Ma, T., Wei, G., and Ni, T.** 2017. Alternative splicing in aging and age-related diseases. *Transl. Med. Aging* **1**: 32-40.
23. **Mazzaferri, E.L., and Jhiang, S.M.** 1994. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med* **97**: 418–428.

24. **McConahey, W.M., Hay, I.D., Woolner, L.B., van Heerden, J.A., and Taylor, W.F.** 1986. Papillary thyroid cancer treated at the Mayo Clinic, 1946-1970: Initial manifestations, pathologic findings, therapy, and outcome. *Mayo Clin Proc* **61**: 978–996.
25. **Miller, R.C., Hiraoka, T., Nakamura, N., and Hara, I.** 1985. In vitro culture of human thyroid cells; methods and application to radiation biology. *J Radiat Res* **26**: 269–282.
26. **Miyake, H., Eto, H., Arakawa, S., Kamidono, S., and Hara, I.** 2002. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. *J Urol* **167**: 1282–1287.
27. **Miyake, H., Okamoto, I., Hara, I., Gohji, K., Yamanaka, K., Arakawa, S., Kamidono, S., and Saya, H.** 1998. Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CD44v8-10/CD44v10 competitive RT-PCR. *Int J Cancer* **79**: 560–564.
28. **Miyauchi, A., Kudo, T., Kihara, M., Higashiyama, T., Ito, Y., Kobayashi, K., and Miya, A.** 2013. Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. *Endocr J* **60**: 415–421.
29. **Miyauchi, A., Kudo, T., Miya, A., Kobayashi, K., Ito, Y., Takamura, Y., Higashiyama, T., Fukushima, M., Kihara, M., Inoue, H., Tomoda, C., Yabuta, T., and Masuoka, H.** 2011. Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy. *Thyroid* **21**: 707–716.
30. **Muramaki, M., Miyake, H., Kamidono, S., and Hara, I.** 2004. Over expression of CD44V8-10 in human bladder cancer cells decreases their interaction with hyaluronic acid and potentiates their malignant progression. *J Urol* **171**: 426–430.
31. **Nagano, O., and Saya, H.** 2004. Mechanism and biological significance of CD44 cleavage. *Cancer Sci* **95**: 930–935.
32. **Okamoto, I., Morisaki, T., Sasaki, J., Miyake, H., Matsumoto, M., Suga, M., Ando, M., and Saya, H.** 1998. Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. *J Natl Cancer Inst* **90**: 307–315.
33. **Olsson, E., Honeth, G., Bendahl, P.O., Saal, L.H., Gruvberger-Saal, S., Ringnér, M., Vallon-Christersson, J., Jönsson, G., Holm, K., Lövgren, K., Fernö, M., Grabau, D., Borg, A., and Hegardt, C.** 2011. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. *BMC Cancer* **11**: 418.
34. **Ponta, H., Sherman, L., and Herrlich, P.A.** 2003. CD44: From adhesion molecules to signalling regulators. *Nat Rev Mol Cell Biol* **4**: 33–45.
35. **Shi, J., Zhou, Z., Di, W., and Li, N.** 2013. Correlation of CD44v6 expression with ovarian cancer progression and recurrence. *BMC Cancer* **13**: 182.
36. **Gospodarowicz, M.K., Brierley, J.D., and Wittekind, C.** 2017. TNM classification of malignant tumours. 8th edition. John Wiley & Sons.
37. **Stamenkovic, I., Aruffo, A., Amiot, M., and Seed, B.** 1991. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. *EMBO J* **10**: 343–348.
38. **Sugitani, I., Kasai, N., Fujimoto, Y., and Yanagisawa, A.** 2004. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. *Surgery* **135**: 139–148.
39. **Takahashi, K., Stamenkovic, I., Cutler, M., Saya, H., and Tanabe, K.K.** 1995. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. *Oncogene* **11**: 2223–2232.
40. **Takano, T., Sumizaki, H., Nakano, K., Matsuzuka, F., Kuma, K., and Amino, N.** 1996. Increased expression of CD44 variants in differentiated thyroid cancers. *Jpn J Cancer Res* **87**: 1245–1250.
41. **Tancini, F., Wu, Y.L., Schweizer, W.B., Gisselbrecht, J.P., Boudon, C., Jarowski, P.D., Beels, M.T., Biaggio, I., and Diederich, F.** 2012. 1-Dicyano-4-[4-(diethylamino)phenyl]buta-1,3-dienes: Structure-Property Relationships. *European J Org Chem* **2012**: 2756–2765.
42. **Weber, G.F., Ashkar, S., and Glimcher, M.J.** 1996. Receptor-Ligand Interaction between CD44 and Osteopontin (Eta-1). *Science* **271**: 509–512.
43. **Weg-Remers, S., Ponta, H., Herrlich, P., and König, H.** 2001. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. *The EMBO journal*, **20**: 4194–4203.
44. **Wu, H.S., Young, M.T., Ituarte, P.H.G., D'Avanzo, A., Duh, Q.Y., Greenspan, F.S., Loh, K.C., and Clark, O.H.** 2000. Death from thyroid cancer of follicular cell origin. *J Am Coll Surg* **191**: 600–606.
45. **Yamaguchi, A., Urano, T., Goi, T., Iida, A., Takeuchi, K., Hirose, K., Nakagawa, G., Urano, T., Furukawa, K., and Shiku, H.** 1996. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. *J Clin Oncol* **14**: 1122–1127.